Previous study have shown that GBM has frequent overexpression of EGFR, which leads to activation of the P13/Akt pathway, associated with adverse clinical outcome and has been suggested to be a therapeutic target41, 42, 43. The gene discussed is AKT1; the disease is glioblastoma.